Daniel Tassé is an accomplished Health Care Executive who has built and led businesses with global footprints in the fields of bio-pharmaceuticals, medical devices, diagnostics and health services.
Mr. Tassé was Chairman and Chief Executive Officer of Ikaria, Inc. from 2008 until the sale of the company to Mallinckrodt in April 2015. Ikaria commercializes to hospitals a proprietary drug/device combination to help ensure best outcomes for patients suffering from many forms of respiratory distress in ICUs. Mr. Tassé transformed Ikaria's business model, drove significant sales and earnings growth, and led the company's expansion to Asia. In 2013, he successfully split Ikaria into two companies (Ikaria and Bellerophon Therapeutics) to best leverage the unique technical, commercial and financial strengths of those businesses. In 2015, Ikaria sold for $2.3 billion, achieving very significant returns for Ikaria's investors.
Prior to Ikaria, Mr. Tassé led the Pharmaceutical Technologies Business Unit of Baxter, a global business with $2 billion in revenue that included anesthesia and critical care, generic drugs, contract manufacturing and drug delivery technologies. Before joining Baxter, Mr. Tassé was based in Melbourne, Australia, where he was responsible for the Austral-Asian business of GlaxoSmithKline, which included vaccines, CNS, anti-infectives, HIV, respiratory and the medicinal opiates API business.
Mr. Tassé is currently a Director of Indivior PLC (London Stock Exchange: INDV), where he is a member of the Audit Committee and the Compensation Committee; of Bellerophon Therapeutics (NASDAQ: BLPH); and of Bio-Q Pharma.
From 2011 until 2015, Mr. Tassé was a Board Director of PhRMA, a member of the Healthcare Leadership Council and a member of the Health Section Governing Board of BIO. Mr. Tassé recently joined the Sheikh Zayed Institute Business Advisory Council in DC.
Daniel holds a B.Sc. in Biochemistry from Universite de Montreal and is fluent in both French and English.